Loading…
Loading…
4169.TWO (TCM Biotech International Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 4169.TWO and 80,000+ other tickers.
See exactly how 4169.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4169.TWO and 80,000+ other tickers.
TCM Biotech International Corp. is a biotechnology enterprise primarily focused on the research and development of pharmaceuticals aimed at preventing and treating liver conditions. The company boasts a diverse product lineup, encompassing solutions for osteoarthritis and osteoporosis, iron supplements, and treatments for urinary system ailments. Furthermore, its offerings extend to expectorants, mucolytic agents, anti-hypertensive preparations, and anti-diabetic medications. Beyond pharmaceuticals, the company also provides anti-adhesion systems, Pellefeel wound care systems, Philips…
No recent news available.